参考文献: [1] Verma V, McMillan MT, Grover S, Simone CB 2nd. Stereotactic Body Radiation Therapy and the Influence of Chemotherapy on Overall Survival for Large (≥5 Centimeter) Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017;97(1):146-154. doi:10.1016/j.ijrobp.2016.09...
[8] B.C. Cho, E. Felip, A.I. Spira, et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. 2023 ESMO, LBA...
非小细胞肺癌（NSCLC）治疗的最新研究进展 引言 肺癌中最常见的类型是非小细胞肺癌（Non-small Cell Lung Cancer, NSCLC），占所有肺癌病例的80%至85%，由于其高发病率及多数患者确诊时已为晚期，使得治疗难度显著增加。近年来，随着医学技术的不断进步，NSCLC的治疗手段日益多样化，涵盖了手术、化疗、放疗、靶向治疗...
approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer [6]Globenewswire: European commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer. https://www.globenewswire.com/ news-release/2022/06/09/2459297/0/en/Europ...
[18]ChoBC, FelipE, SpiraAI, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, ...
小编整理了帕博丽珠单抗在非小细胞肺癌(Non Small Cell Lung Cancer,NSCLC)和小细胞肺癌(Small Cell Lung Cancer,SCLC)中的系列研究,有助于我们更深入的认识PD-1抗体—帕博利珠单抗。 系列研究概要 非小细胞肺癌 拉开研究序幕 1.KEYNOTE-001:初步确立了K药的使用方法和剂量,奠定了PD-L1的检测方法和cut-off值,...
[6] Ahn MJ, Tanaka K, Paz-Ares L, et al; TROPION-Lung01 Trial Investigators. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2024 Sep 9:JCO2401544...
[23] Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial[J]. JAMA Oncol,...
[18]ChoBC, FelipE, SpiraAI, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase Ⅲ, global, randomized, controlled trial[J]. Ann Oncol, 2023, ...
[2] Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023 Jul 17:S0923-7534(23)00764-0 ...